{'52WeekChange': 0.24447668,
 'SandP52WeekChange': None,
 'address1': '5 Science Park',
 'address2': '395 Winchester Avenue',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 34.35,
 'askSize': 800,
 'averageDailyVolume10Day': 266075,
 'averageVolume': 654192,
 'averageVolume10days': 266075,
 'beta': None,
 'beta3Year': None,
 'bid': 34.05,
 'bidSize': 800,
 'bookValue': 5.474,
 'category': None,
 'circulatingSupply': None,
 'city': 'New Haven',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 35.22,
 'dayLow': 33.71,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -18.81,
 'enterpriseToRevenue': 23.8,
 'enterpriseValue': 1075733760,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 33.406002,
 'fiftyTwoWeekHigh': 61.57,
 'fiftyTwoWeekLow': 15.19,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 24446947,
 'forwardEps': -2.75,
 'forwardPE': -12.389091,
 'fromCurrency': None,
 'fullTimeEmployees': 133,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.13054,
 'heldPercentInstitutions': 0.76769996,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/arvinas.com',
 'longBusinessSummary': 'Arvinas, Inc., a clinical-stage biopharmaceutical '
                        'company, engages in the discovery, development, and '
                        'commercialization of therapies to degrade '
                        "disease-causing proteins. The company's lead products "
                        'include ARV-110, proteolysis targeting chimeras '
                        '(PROTAC) that is in phase I clinical trial targeting '
                        'the androgen receptor (AR) protein for the treatment '
                        'of men with metastatic castration-resistant prostate '
                        'cancer; and ARV-471, a PROTAC targeting the estrogen '
                        'receptor protein for the treatment of patients with '
                        'metastatic ER positive/HER2 negative breast cancer. '
                        'It is also developing other PROTACs for degrading AR '
                        'and other clinically relevant AR point mutations; and '
                        'various other products for the treatment of '
                        'neurodegenerative diseases, including tauopathies. '
                        'The company has collaborations with Pfizer Inc., '
                        'Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer '
                        'AG. Arvinas, Inc. was founded in 2015 and is based in '
                        'New Haven, Connecticut.',
 'longName': 'Arvinas, Inc.',
 'market': 'us_market',
 'marketCap': 1333826816,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_243040896',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -77626904,
 'nextFiscalYearEnd': 1640908800,
 'open': 34.68,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '203 535 1456',
 'previousClose': 34.36,
 'priceHint': 2,
 'priceToBook': 6.223968,
 'priceToSalesTrailing12Months': 29.509693,
 'profitMargins': -1.7174201,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 35.22,
 'regularMarketDayLow': 33.71,
 'regularMarketOpen': 34.68,
 'regularMarketPreviousClose': 34.36,
 'regularMarketPrice': 34.68,
 'regularMarketVolume': 348253,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 39149600,
 'sharesPercentSharesOut': 0.1069,
 'sharesShort': 4186537,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2900666,
 'shortName': 'Arvinas, Inc.',
 'shortPercentOfFloat': 0.135,
 'shortRatio': 5.77,
 'startDate': None,
 'state': 'CT',
 'strikePrice': None,
 'symbol': 'ARVN',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.235,
 'twoHundredDayAverage': 43.41669,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '5ab3d208-4f36-3880-916e-a34548e61b36',
 'volume': 348253,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.arvinas.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '06511'}